2020
Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies
Ganesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik PD, D’Souza D. Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. The International Journal Of Neuropsychopharmacology 2020, 23: 559-570. PMID: 32385508, PMCID: PMC7710917, DOI: 10.1093/ijnp/pyaa031.Peer-Reviewed Original ResearchMeSH KeywordsAdultCannabinoid Receptor AgonistsDose-Response Relationship, DrugDronabinolFemaleHumansMalePsychoses, Substance-InducedRandomized Controlled Trials as TopicConceptsHuman laboratory studiesHealthy human volunteersPositive symptomsTHC dosePsychotomimetic effectsHuman volunteersPsychosis-like effectsNegative Syndrome ScaleProfile of symptomsCrossover studyIntravenous administrationMotor retardationHealthy individualsSyndrome ScaleSymptomsNegative syndromeSomatic concernsSubstance useConceptual disorganizationFrequent cannabisMultiple studiesMeaningful increase
2016
Human Laboratory Studies on Cannabinoids and Psychosis
Sherif M, Radhakrishnan R, D’Souza D, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry 2016, 79: 526-538. PMID: 26970363, DOI: 10.1016/j.biopsych.2016.01.011.BooksConceptsCannabinoid agonistsPsychotomimetic effectsAcute psychotomimetic effectsHealthy control subjectsCrossover laboratory studyEffects of ketamineHuman laboratory studiesGamma-aminobutyric acidHealthy human subjectsSelf-medication hypothesisTransient exacerbationAntipsychotic medicationControl subjectsDopamine metabolismGlutamate systemDopamine releasePsychotomimetic drugsCognitive symptomsDrug AdministrationAgonistsMagnitude of effectSymptomsSchizophreniaCannabinoidsLaboratory studies
2011
The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories
Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D’Souza D, The Yale THC Study Group. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2011, 219: 885-896. PMID: 21845389, DOI: 10.1007/s00213-011-2417-y.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxietyDronabinolDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMarijuana SmokingMiddle AgedParanoid DisordersRandomized Controlled Trials as TopicTime FactorsYoung AdultConceptsAdverse eventsPost-study periodCareful subject selectionMinor adverse eventsPhysical adverse eventsFrequent side effectsLong-term followCannabinoid receptor systemFaster infusion rateCannabinoid receptor ligandsIntravenous THCPlacebo infusionCannabinoid systemInfusion rateStudy participationSide effectsAbuse liabilityHigh dosesReceptor systemΔ9-tetrahydrocannabinolInfusionPsychoactive effectsReceptor ligandsTest daySubjects